Human Pharmaceutical and Medicinal Product Manufacturing
ANZSIC class 1841 · 21 mergers
Since February 2026, the ACCC has reviewed 21 acquisitions in the Human Pharmaceutical and Medicinal Product Manufacturing industry (ANZSIC class 1841): 13 notified mergers and 8 waiver applications. Outcomes so far: 18 approved, 2 not approved and 1 still under assessment. The most frequent acquirers are Eli Lilly (6) and Gilead (2). Completed Phase 1 reviews took a median of 17 business days, and waivers a median of 18 business days. The most recent, Sun Pharma - Organon, was lodged on 22 October 2026.
Total reviews
21
Phase 2 reviews
0
Waivers
8
Under assessment
1
Mergers in this industry
- Sun Pharma - OrganonUnder assessment
- Kirin – Jamieson WellnessApproved
- Northpharm Services - Wesley Pharmacy GroupApproved
- Merck KGaA–Bio-TechneApproved
- Eli Lilly – Merida BiosciencesApproved
- Kirin – Jamieson WellnessNot approved
- Eli Lilly - AtaiBeckley Inc.Approved
- Movac – Advanced NavigationApproved
- AbbVie - ApogeeApproved
- Vertex – CrineticsApproved
- Apollo - Bayer Asset ManagementApproved
- Apollo Capital – CuriaApproved
- CVC Capital Partners and Groupe Bruxelles Lambert – RecordatiApproved
- Eli Lilly - Kelonia TherapeuticsApproved
- Gilead - OuroApproved
- Eli Lilly – acquisition of licence from CSL BehringApproved
- Francisco Partners - Blackline SafetyApproved
- Eli Lilly - Orna TherapeuticsApproved
- CVC Capital Partners – Marathon Asset ManagementApproved
- Gilead - ArcellxApproved
- Eli Lilly – Orna TherapeuticsNot approved